A European-based pharmaceutical company wanted to improve their pancreatic enzyme product (PEP) delivery to patients who have difficulty swallowing several capsules a day – especially children with cystic fibrosis and other conditions. Providing a broad dosage range for optimal symptom control and precise dosing was also a requirement.
